ArticleCancers2025

Venetoclax-Rituximab and Emerging Treatment Strategies After c-BTKi Exposure in Relapsed/Refractory CLL: A Real-World Cohort and Literature Overview.

Maria Dimou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.